Literature DB >> 12872133

A transgenic mouse model of the ubiquitin/proteasome system.

Kristina Lindsten1, Victoria Menéndez-Benito, Maria G Masucci, Nico P Dantuma.   

Abstract

Impairment of the ubiquitin/proteasome system has been proposed to play a role in neurodegenerative disorders such as Alzheimer and Parkinson diseases. Although recent studies confirmed that some disease-related proteins block proteasomal degradation, and despite the existence of excellent animal models of both diseases, in vivo data about the system are lacking. We have developed a model for in vivo analysis of the ubiquitin/proteasome system by generating mouse strains transgenic for a green fluorescent protein (GFP) reporter carrying a constitutively active degradation signal. Administration of proteasome inhibitors to the transgenic animals resulted in a substantial accumulation of GFP in multiple tissues, confirming the in vivo functionality of the reporter. Moreover, accumulation of the reporter was induced in primary neurons by UBB+1, an aberrant ubiquitin found in Alzheimer disease. These transgenic animals provide a tool for monitoring the status of the ubiquitin/proteasome system in physiologic or pathologic conditions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12872133     DOI: 10.1038/nbt851

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  81 in total

1.  A photoconvertible reporter of the ubiquitin-proteasome system in vivo.

Authors:  Geert Hamer; Olli Matilainen; Carina I Holmberg
Journal:  Nat Methods       Date:  2010-05-09       Impact factor: 28.547

2.  Glycation-altered proteolysis as a pathobiologic mechanism that links dietary glycemic index, aging, and age-related disease (in nondiabetics).

Authors:  Tomoaki Uchiki; Karen A Weikel; Wangwang Jiao; Fu Shang; Andrea Caceres; Dorota Pawlak; James T Handa; Michael Brownlee; Ram Nagaraj; Allen Taylor
Journal:  Aging Cell       Date:  2011-11-15       Impact factor: 9.304

Review 3.  Protein quality control during erythropoiesis and hemoglobin synthesis.

Authors:  Eugene Khandros; Mitchell J Weiss
Journal:  Hematol Oncol Clin North Am       Date:  2010-12       Impact factor: 3.722

4.  Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling.

Authors:  Natura Myeku; Catherine L Clelland; Sheina Emrani; Nikolay V Kukushkin; Wai Haung Yu; Alfred L Goldberg; Karen E Duff
Journal:  Nat Med       Date:  2015-12-21       Impact factor: 53.440

5.  Single neuron ubiquitin-proteasome dynamics accompanying inclusion body formation in huntington disease.

Authors:  Siddhartha Mitra; Andrey S Tsvetkov; Steven Finkbeiner
Journal:  J Biol Chem       Date:  2008-12-10       Impact factor: 5.157

Review 6.  The interplay between autophagy and the ubiquitin-proteasome system in cardiac proteotoxicity.

Authors:  Changhua Wang; Xuejun Wang
Journal:  Biochim Biophys Acta       Date:  2014-08-01

7.  Neuronal induction of the immunoproteasome in Huntington's disease.

Authors:  Miguel Díaz-Hernández; Félix Hernández; Ester Martín-Aparicio; Pilar Gómez-Ramos; María A Morán; José G Castaño; Isidro Ferrer; Jesús Avila; José J Lucas
Journal:  J Neurosci       Date:  2003-12-17       Impact factor: 6.167

8.  Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex.

Authors:  Hui-Hua Li; Vishram Kedar; Chunlian Zhang; Holly McDonough; Ranjana Arya; Da-Zhi Wang; Cam Patterson
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

Review 9.  Priming the proteasome by protein kinase G: a novel cardioprotective mechanism of sildenafil.

Authors:  Hanming Zhang; Xuejun Wang
Journal:  Future Cardiol       Date:  2015-03

10.  Transgenic mice overexpressing reticulon 3 develop neuritic abnormalities.

Authors:  Xiangyou Hu; Qi Shi; Xiangdong Zhou; Wanxia He; Hong Yi; Xinghua Yin; Marla Gearing; Allan Levey; Riqiang Yan
Journal:  EMBO J       Date:  2007-05-03       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.